We Fuel a Network of Leaders that Drive Virginia Bioscience
We are made up of the people who do the research, development and commercialization of biosciences in Virginia, and the suppliers, consultants, attorneys, accountants and others who work to support the industry.
Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
Life science companies in Virginia.
Life Science contributes $8B to Virginia's economy.
Employed by Life Science companies in Virginia.
$77,848 Average Wage
Average earnings of life science workers in Virginia.
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
Solving the Unsolvable: Could Quantum and other Non-traditional Computing hold the key to accelerating drug development?
11:00 am – 12:30 pm EST
Study aiming to define acute traumatic encephalopathy (ATE) published by leading neurology journal
BrainBox HeadSmart II Study Investigators Aim to Provide Clinicians with First-Ever Biomarkers and other Functional measurements for Acute Traumatic Encephalopathy (ATE.) A clinical trial of multi-modal diagnostic/prognostic test, already underway, is published in Frontiers in Neurology/NeuroTrauma. Investigators in a major clinical trial of patients with mild traumatic brain injury (mTBI or concussion) describe for the …
Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion
Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against …
HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda
HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited (“Takeda”) for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear’s exclusive collaboration with Takeda to discover novel targets and develop therapeutics for …